STOCK TITAN

Liquidia Corporation - LQDA STOCK NEWS

Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.

Liquidia Corporation (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company committed to enhancing drug delivery and efficacy through its proprietary PRINT® technology. The company focuses on the development, manufacturing, and commercialization of innovative therapies for pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia’s flagship product, YUTREPIA™, is an investigational inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension (PAH) and PH-ILD. This product aims to improve exercise ability and quality of life for patients.

Liquidia is actively advancing its product pipeline, which includes L606, an investigational sustained-release formulation of treprostinil administered through a next-generation nebulizer. Currently, L606 is under evaluation in an open-label study and aims to extend drug exposure while minimizing local irritation in the lungs.

In addition to these developments, Liquidia has a valuable collaboration with leading pharmaceutical companies, leveraging its PRINT® technology for broader therapeutic areas. This technology enables precise production of uniform drug particles, enhancing safety and efficacy, and can be applied to various therapeutic areas and routes of administration.

Recent achievements include the promotion of key leadership within the company as they prepare for the potential FDA approval and launch of YUTREPIA. The company has also successfully navigated regulatory and legal challenges, ensuring a clear path for YUTREPIA’s market entry.

Financially, Liquidia has demonstrated robust growth, reporting significant revenue from its partnership with Sandoz for the commercial sale of Treprostinil Injection. The company has also secured substantial funding through strategic agreements, bolstering its cash reserves for continued research and development efforts.

Liquidia remains dedicated to transforming patient care by addressing unmet needs with innovative drug delivery solutions and is poised to make significant strides in the biopharmaceutical industry.

Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) reported its Q3 2022 financial results, maintaining revenue at $3.2 million year-over-year. The company is preparing to launch YUTREPIA™ for PAH and PH-ILD following legal victories against United Therapeutics. Liquidia's cash increased to $98.3 million, up from $57.5 million in December 2021. However, the net loss widened to $9.1 million compared to $7.3 million in Q3 2021, attributed to rising administrative expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
-
Rhea-AI Summary

Anavasi Diagnostics, a medical technology firm, has elected three new board members: Bryan Crane, PhD, from Illumina, Arthur Kirsch from Liquidia Corp, and David Vied from Cyanotech Corporation. This expansion aims to leverage their extensive industry experience to enhance Anavasi's growth as it progresses through clinical trials and product development. Nelson Patterson, CEO, expressed optimism about the fresh perspectives these members will bring. Anavasi has secured $6 million in seed funding and is currently in a $20 million Series A fundraising round.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
management
-
Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) will release its third quarter 2022 financial results on November 8, 2022. A conference call and webcast will follow at 8:30 a.m. ET for discussion of the results and corporate updates. Interested parties can join the live call by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international), entering conference code 7467713. Additionally, a webcast will be accessible on Liquidia’s website for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
conferences earnings
Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) announced that the Precedential Opinion Panel of the USPTO denied United Therapeutics' request to review the PTAB decision that invalidated claims of U.S. Patent No. 10,716,793. The PTAB had ruled the claims unpatentable based on prior art presented by Liquidia. The decision supports Liquidia's position as it seeks final approval for YUTREPIA, its inhalation powder for treating pulmonary arterial hypertension (PAH). CEO Roger Jeffs expressed confidence in the ongoing rehearing process, anticipating a favorable outcome by mid-2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
-
Rhea-AI Summary

Liquidia Corporation (LQDA) announced data presentations for YUTREPIA™ (treprostinil) inhalation powder at the CHEST 2022 Annual Meeting. The data includes findings on higher dose efficacy compared to lower doses and the product's robustness in misuse scenarios. YUTREPIA is designed to treat pulmonary arterial hypertension (PAH) and was granted a tentative FDA approval in November 2021. The presentations will be accessible on the company's website post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
none
-
Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) reported a favorable District Court ruling regarding U.S. Patent No. 9,593,066 (‘066 Patent) but an unfavorable outcome for U.S. Patent No. 10,716,793 (‘793 Patent). The court found five of six asserted claims of the ‘066 patent invalid and ruled that the valid claim was not infringed. All claims of the '793 patent were previously invalidated by the PTAB, impacting the FDA approval pathway for YUTREPIA™ (treprostinil) inhalation powder. The company plans to appeal the decision and has scheduled a conference call for September 1, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.77%
Tags
conferences
Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) announced the grant of inducement stock options totaling 7,000 shares to newly hired non-executive employees under the 2022 Inducement Plan. Each option is priced at $7.44 per share, the closing price on August 19, 2022. The options have a vesting schedule of four years, with 25% vesting on the first anniversary and the remainder vesting monthly. This grant aligns with Nasdaq Listing Rule 5635(c)(4) to attract new talent. Liquidia focuses on developing products for pulmonary hypertension and other applications of its PRINT® Technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
none
-
Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) reported its second-quarter financial results for 2022, showing revenues of $3.9 million, up from $3.4 million the previous year. The company has strengthened its financial position with $103.8 million in cash, thanks to a recent equity offering of $54.5 million. Liquidia is focusing on launching YUTREPIA™ inhalation powder, pending regulatory approval, after a favorable ruling in Hatch-Waxman litigation. The company expects to seek a second indication for YUTREPIA in 2024 without additional studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
-
Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) will announce its second quarter 2022 financial results on August 11, 2022, with a conference call scheduled for 8:30 a.m. ET. The call will cover financial results and a corporate update. Interested parties can join by phone or access a webcast, which will be archived for 30 days. Liquidia focuses on developing treatments for pulmonary hypertension, including its inhalation powder YUTREPIA™. For more information, visit Liquidia's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences earnings
Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) released clinical data from the INSPIRE study on YUTREPIA™ (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH). The study demonstrated effective titration, achieving therapeutic levels within two months, and maintaining safety with primarily mild to moderate side effects. Out of 121 patients, 93% completed the two-month phase, with significant improvement in NYHA functional class. Although the study wasn't designed for definitive efficacy conclusions, preliminary results indicate positive clinical impact. Long-term safety data will continue to emerge from ongoing studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags

FAQ

What is the current stock price of Liquidia Corporation (LQDA)?

The current stock price of Liquidia Corporation (LQDA) is $11.1 as of December 20, 2024.

What is the market cap of Liquidia Corporation (LQDA)?

The market cap of Liquidia Corporation (LQDA) is approximately 912.4M.

What is Liquidia Corporation's primary focus?

Liquidia Corporation focuses on developing, manufacturing, and commercializing innovative therapies for pulmonary hypertension and pulmonary hypertension associated with interstitial lung disease using its proprietary PRINT® technology.

What is YUTREPIA?

YUTREPIA is an investigational inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What is PRINT® technology?

PRINT® technology is Liquidia's proprietary particle engineering platform that enables the precise production of uniform drug particles, enhancing safety and efficacy and applicable to various therapeutic areas and routes of administration.

What products are in Liquidia’s pipeline?

In addition to YUTREPIA, Liquidia is developing L606, an investigational sustained-release formulation of treprostinil administered through a next-generation nebulizer.

How does Liquidia generate revenue?

Liquidia generates revenue primarily from the sale of Treprostinil Injection through a partnership with Sandoz, as well as through strategic collaborations leveraging its PRINT® technology.

What recent leadership changes have occurred at Liquidia?

Recent leadership changes include the promotion of Michael Kaseta to Chief Operating Officer in addition to his role as Chief Financial Officer, and Michael Hunter to Senior Vice President of Manufacturing Operations.

What is the current status of YUTREPIA’s FDA approval?

YUTREPIA has received tentative approval from the FDA for the treatment of PAH, and Liquidia has filed an amendment to include PH-ILD. The FDA is expected to take final action on the amended NDA.

What are the financial highlights for Liquidia?

Liquidia reported significant revenue growth from its partnership with Sandoz, increased research and development expenses focused on YUTREPIA and L606, and strengthened cash reserves through strategic funding agreements.

What legal challenges has Liquidia faced?

Liquidia has navigated patent litigation and regulatory challenges, recently overcoming an injunction that had prevented FDA approval of YUTREPIA, and is actively defending against ongoing patent infringement claims.

How can I learn more about Liquidia Corporation?

For more information, visit Liquidia's official website at www.liquidia.com.

Liquidia Corporation

Nasdaq:LQDA

LQDA Rankings

LQDA Stock Data

912.38M
60.46M
19.49%
54.31%
12.25%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MORRISVILLE